Category Archives: Switzerland

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir (Mayret) in Chronic Hepatitis C Patients (SMART-C)

Clinical Trials

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/ Pibrentasvir (Mayret) in Chronic Hepatitis C Patients (SMART-C)

Data has shown that direct-acting antiviral (DAA) regimen of glecaprevir (300mg)/pibrentasvir (120mg), a protease inhibitor and NS5A inhibitor respectively, provides key features for HCV treatment simplification.

Eligible participants (naïve pre-cirrhosis chronic HCV patients) will be randomized (1:2) to the standard or simplified monitoring arm and will receive treatment for 8 weeks.

One post-treatment visit will be conducted 12 weeks after the final dose of study medication to evaluate the proportion of patients with undetectable HCV RNA at this time point (SVR12).

To read about the clinical trial, click here

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

Clinical Trials

The study is evaluating the safety and effectiveness of Viekira Pak to treat pediatric patients with chronic hepatitis C genotypes 1 and 4.  Viekira Pak is already approved by the Food and Drug Administration to treat adults with hepatitis C.  This is the first clinical trial of Viekira Pak to treat pediatric patients.

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (ZIRCON)

To view the entire clinical trial description, click here

 

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmailFacebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow Us
FacebooktwitterFacebooktwitter